{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:34:24Z","timestamp":1791408864620,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315969, 320107"],"award-info":[{"award-number":["315969, 320107"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["315969, 320107"],"award-info":[{"award-number":["315969, 320107"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Finnish Ministry of Social Affairs and Health: developmental fund for Niuvanniemi Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapses remain common among individuals with schizophrenia indicating a need for improved treatments. Creating a completely new drug molecule is expensive and time consuming, and therefore drug repurposing should be considered. Aim of this study was to investigate the risk of psychiatric rehospitalization associated with use of adenosine modulators (AMs) and calcium channel blockers (CCBs) in schizophrenia. Individuals diagnosed with schizophrenia (<jats:italic>N<\/jats:italic>\u2009=\u200961,889) in inpatient care between 1972\u20132014 in Finland were included. The follow-up lasted from 1996 to 2017. Main exposures were use of AMs (allopurinol and dipyridamole) and CCBs (dihydropyridines, diltiazem, and verapamil). Thiazide diuretics were used as a negative control. Within-individual models in stratified Cox regression were used and adjusted hazard ratios (HR) with 95% confidence intervals (CIs) are reported. Use of AMs was associated with a reduced risk of psychiatric rehospitalization on drug class level (HR 0.74, 95% CI 0.65\u20130.84, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), as well as on the level of individual drugs (allopurinol HR 0.82, 95% CI 0.70\u20130.97, <jats:italic>P<\/jats:italic>\u2009=\u20090.02; dipyridamole HR 0.65, 95% CI 0.55\u20130.77, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). Use of CCBs was associated with a reduced risk of psychiatric rehospitalization on drug class level (HR 0.81, 95% CI 0.77\u20130.86, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). From the different CCBs, only exposure to dihydropyridines was associated with a reduced risk (HR 0.79, 95% CI 0.74\u20130.84, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). No effect was observed for the negative control, thiazide diuretics (HR 0.96, 0.90\u20131.02, <jats:italic>P<\/jats:italic>\u2009=\u20090.20). The effects of dipyridamole and dihydropyridines were more pronounced among younger persons and combination of AMs, and CCBs was associated with a lower risk than either drug class as monotherapy. These results indicate a need for randomized controlled trials of these drugs.<\/jats:p>","DOI":"10.1038\/s41537-020-00135-y","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T11:05:39Z","timestamp":1611227139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Adenosine modulators and calcium channel blockers as add-on treatment for schizophrenia"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5627-2388","authenticated-orcid":false,"given":"Jonne","family":"Lintunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"L\u00e4hteenvuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tanskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-934X","authenticated-orcid":false,"given":"Heidi","family":"Taipale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"135_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","volume":"388","author":"MJ Owen","year":"2016","unstructured":"Owen, M. J., Sawa, A. & Mortensen, P. B. Schizophrenia. Lancet 388, 86\u201397 (2016).","journal-title":"Lancet"},{"key":"135_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1017\/S0033291719001296","volume":"50","author":"JM Rubio","year":"2020","unstructured":"Rubio, J. M. et al. Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study. Psychol. Med. 50, 1356\u20131367 (2020).","journal-title":"Psychol. Med."},{"key":"135_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1021\/acschemneuro.8b00205","volume":"10","author":"SG Lago","year":"2019","unstructured":"Lago, S. G. & Bahn, S. Clinical trials and therapeutic rationale for drug repurposing in schizophrenia. ACS Chem. Neurosci. 10, 58\u201378 (2019).","journal-title":"ACS Chem. Neurosci."},{"key":"135_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.pnpbp.2006.02.002","volume":"30","author":"DR Lara","year":"2006","unstructured":"Lara, D. R., Dall\u2019Igna, O. P., Ghisolfi, E. S. & Brunstein, M. G. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 30, 617\u2013629 (2006).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"135_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.pnpbp.2004.11.008","volume":"29","author":"S Akhondzadeh","year":"2005","unstructured":"Akhondzadeh, S., Safarcherati, A. & Amini, H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29, 253\u2013259 (2005).","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"135_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.schres.2013.06.038","volume":"149","author":"T Hirota","year":"2013","unstructured":"Hirota, T. & Kishi, T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr. Res. 149, 88\u201395 (2013).","journal-title":"Schizophr. Res."},{"key":"135_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/jop.2015.0128","volume":"32","author":"M Rogosnitzky","year":"2016","unstructured":"Rogosnitzky, M., Isakov, I., Wlassoff, W., Ingram, A. & Barishak, Y. R. Ocular applications of dipyridamole: a review of indications and routes of administration. J. Ocul. Pharmacol. Ther. 32, 83\u201389 (2016).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"135_CR9","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth, N., Merriman, T. R. & Stamp, L. K. Gout. Lancet 388, 2039\u20132052 (2016).","journal-title":"Lancet"},{"key":"135_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4088\/JCP.v66n0209","volume":"66","author":"MG Brunstein","year":"2005","unstructured":"Brunstein, M. G., Ghisolfi, E. S., Ramos, F. L. P. & Lara, D. R. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J. Clin. Psychiatry 66, 213\u2013219 (2005).","journal-title":"J. Clin. Psychiatry"},{"key":"135_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.schres.2008.12.028","volume":"109","author":"FB Dickerson","year":"2009","unstructured":"Dickerson, F. B. et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr. Res. 109, 66\u201369 (2009).","journal-title":"Schizophr. Res."},{"key":"135_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.schres.2012.02.014","volume":"138","author":"M Weiser","year":"2012","unstructured":"Weiser, M. et al. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 138, 35\u201338 (2012).","journal-title":"Schizophr. Res."},{"key":"135_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2710.2000.00273.x","volume":"25","author":"Shasavand Akhondzadeh","year":"2000","unstructured":"Akhondzadeh, Shasavand, Jamilian, Shabestari & Kamalipour Dipyridamole in the treatment of schizophrenia: adenosine\u2013dopamine receptor interactions. J. Clin. Pharm. Ther. 25, 131\u2013137 (2000).","journal-title":"J. Clin. Pharm. Ther."},{"key":"135_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.neuron.2018.03.017","volume":"98","author":"E Nanou","year":"2018","unstructured":"Nanou, E. & Catterall, W. A. Calcium channels, synaptic plasticity, and neuropsychiatric disease. Neuron 98, 466\u2013481 (2018).","journal-title":"Neuron"},{"key":"135_CR15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.ejmg.2015.10.008","volume":"58","author":"AV Kotlar","year":"2015","unstructured":"Kotlar, A. V., Mercer, K. B., Zwick, M. E. & Mulle, J. G. New discoveries in schizophrenia genetics reveal neurobiological pathways: a review of recent findings. Eur. J. Med. Genet. 58, 704\u2013714 (2015).","journal-title":"Eur. J. Med. Genet."},{"key":"135_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/mp.2014.143","volume":"20","author":"T Yoshimizu","year":"2015","unstructured":"Yoshimizu, T. et al. Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol. Psychiatry 20, 162\u2013169 (2015).","journal-title":"Mol. Psychiatry"},{"key":"135_CR17","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamapsychiatry.2018.3907","volume":"76","author":"JF Hayes","year":"2019","unstructured":"Hayes, J. F. et al. Association of hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry 76, 382\u2013390 (2019).","journal-title":"JAMA Psychiatry"},{"key":"135_CR18","doi-asserted-by":"crossref","unstructured":"M\u00fcller, N. COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders. Front. Psychiatry 10, 375 (2019).","DOI":"10.3389\/fpsyt.2019.00375"},{"key":"135_CR19","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.neuropharm.2011.01.048","volume":"62","author":"D Boison","year":"2012","unstructured":"Boison, D., Singer, P., Shen, H. Y., Feldon, J. & Yee, B. K. Adenosine hypothesis of schizophrenia - Opportunities for pharmacotherapy. Neuropharmacology 62, 1527\u20131543 (2012).","journal-title":"Neuropharmacology"},{"key":"135_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.neuropharm.2015.10.032","volume":"104","author":"U Kr\u00fcgel","year":"2016","unstructured":"Kr\u00fcgel, U. Purinergic receptors in psychiatric disorders. Neuropharmacology 104, 212\u2013225 (2016).","journal-title":"Neuropharmacology"},{"key":"135_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/bph.13364","volume":"173","author":"LE Laskaris","year":"2016","unstructured":"Laskaris, L. E. et al. Microglial activation and progressive brain changes in schizophrenia. Br. J. Pharmacol. 173, 666\u2013680 (2016).","journal-title":"Br. J. Pharmacol."},{"key":"135_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd2638","volume":"7","author":"G Hask\u00f3","year":"2008","unstructured":"Hask\u00f3, G., Linden, J., Cronstein, B. & Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759\u2013770 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"135_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2165\/0023210-200822120-00002","volume":"22","author":"JA Siuciak","year":"2008","unstructured":"Siuciak, J. A. The role of phosphodiesterases in schizophrenia: therapeutic implications. CNS Drugs 22, 983\u2013993 (2008).","journal-title":"CNS Drugs"},{"key":"135_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000319072","volume":"30","author":"S Guo","year":"2010","unstructured":"Guo, S., Stins, M., Ning, M. & Lo, E. H. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc. Dis. 30, 290\u2013296 (2010).","journal-title":"Cerebrovasc. Dis."},{"key":"135_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","volume":"28","author":"HH Kim","year":"2008","unstructured":"Kim, H. H. & Liao, J. K. Translational therapeutics of dipyridamole. Arterioscler. Thromb. Vasc. Biol. 28, 39\u201342 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"135_CR26","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. Aggrenox\u00ae prescribing information https:\/\/docs.boehringer-ingelheim.com\/PrescribingInformation\/PIs\/AggrenoxCaps\/Aggrenox.pdf (2020)."},{"key":"135_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133980","volume":"10","author":"M Yamaguchi","year":"2015","unstructured":"Yamaguchi, M. et al. The effects of xanthine oxidoreductase inhibitors on oxidative stress markers following global brain ischemia reperfusion injury in C57BL\/6 Mice. PLoS ONE 10, e0133980 (2015).","journal-title":"PLoS ONE"},{"key":"135_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pneurobio.2015.09.002","volume":"134","author":"S Heyes","year":"2015","unstructured":"Heyes, S. et al. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog. Neurobiol. 134, 36\u201354 (2015).","journal-title":"Prog. Neurobiol."},{"key":"135_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/mp.2016.86","volume":"21","author":"A Cipriani","year":"2016","unstructured":"Cipriani, A. et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol. Psychiatry 21, 1324\u20131332 (2016).","journal-title":"Mol. Psychiatry"},{"key":"135_CR30","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0024-3205(97)00881-3","volume":"61","author":"S Uchida","year":"1997","unstructured":"Uchida, S., Yamada, S., Nagai, K., Deguchi, Y. & Kimura, R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 61, 2083\u20132090 (1997).","journal-title":"Life Sci."},{"key":"135_CR31","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jacc.2013.02.058","volume":"61","author":"JD Wessler","year":"2013","unstructured":"Wessler, J. D., Grip, L. T., Mendell, J. & Giugliano, R. P. The P-glycoprotein transport system and cardiovascular drugs. J. Am. Coll. Cardiol. 61, 2495\u20132502 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"135_CR32","doi-asserted-by":"publisher","first-page":"484963","DOI":"10.1155\/2015\/484963","volume":"2015","author":"FG Hoosain","year":"2015","unstructured":"Hoosain, F. G. et al. Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. Biomed. Res. Int. 2015, 484963 (2015).","journal-title":"Biomed. Res. Int."},{"key":"135_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12911-015-0140-z","volume":"15","author":"A Tanskanen","year":"2015","unstructured":"Tanskanen, A. et al. From prescription drug purchases to drug use periods \u2013 a second generation method (PRE2DUP). BMC Med. Inform. Decis. Mak. 15, 1\u201313 (2015).","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"135_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/CLEP.S116160","volume":"8","author":"H Taipale","year":"2016","unstructured":"Taipale, H. et al. Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons. Clin. Epidemiol. 8, 363\u2013371 (2016).","journal-title":"Clin. Epidemiol."},{"key":"135_CR35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","volume":"10","author":"TM Laursen","year":"2014","unstructured":"Laursen, T. M., Nordentoft, M. & Mortensen, P. B. Excess early mortality in schizophrenia. Annu. Rev. Clin. Psychol. 10, 425\u2013448 (2014).","journal-title":"Annu. Rev. Clin. Psychol."},{"key":"135_CR36","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","volume":"44","author":"H Taipale","year":"2018","unstructured":"Taipale, H., Meht\u00e4l\u00e4, J., Tanskanen, A. & Tiihonen, J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia - a nationwide study with 20-year follow-up. Schizophr. Bull. 44, 1381\u20131387 (2018).","journal-title":"Schizophr. Bull."},{"key":"135_CR37","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","volume":"367","author":"P Lichtenstein","year":"2012","unstructured":"Lichtenstein, P. et al. Medication for attention deficit\u2013hyperactivity disorder and criminality. N. Engl. J. Med. 367, 2006\u20132014 (2012).","journal-title":"N. Engl. J. Med."}],"container-title":["npj Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-020-00135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-020-00135-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-020-00135-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:17:22Z","timestamp":1670023042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-020-00135-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1038\/s41537-020-00135-y","relation":{},"ISSN":["2334-265X"],"issn-type":[{"value":"2334-265X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"23 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L. declares no conflicts of interest. J.T., H.T., and A.T. have participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to their employing institution. H.T. reports personal fees from Janssen-Cilag. J.T. reports personal fees from Eli Lilly, Janssen-Cilag, Lundbeck, and Otsuka; and is a member of advisory board for Lundbeck. M.L. is a board member of Genomi Solutions ltd. and DNE ltd., has reports personal fees from Sunovion ltd., Janssen-Cilag and Orion Pharma ltd., and research funding from The Finnish Medical Foundation and Emil Aaltonen Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}